IMO from a risk / maturity perspective RAC are best to get some patients into the efficacy stage of the initial EM AML trial and then interim data analysis before initiating a trial in the US. Best to get the protocol bedded down through the first trial and get some experience treating patients at low dose before initiating a pivotal trial in the US (which will then be fundamental for future FDA approval).
I think this will also allow time for other forms of administration such as peripheral IV or oral to be completed. I suspect the existing trial could be amended with additional cohort(s) of patients to validate other forms of administration.
Ann: Race investor briefing invitation, page-16
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.68 |
Change
0.020(1.20%) |
Mkt cap ! $286.2M | |||
| Open | High | Low | Value | Volume |
| $1.68 | $1.68 | $1.61 | $177.8K | 108.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1100 | $1.64 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.68 | 4999 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |